Journal of Clinical Oncology
Articles in this Issue
Racial disparities and shared genomic drivers in prostate cancer.
e17112 Background: Prostate cancer (PC) is characterized by significant genomic heterogeneity, which drastically impacts its clinical course and therapeut...
Use of a combined artificial intelligent system for lung cancer stage prediction and classification.
e20037 Background: To date, the investigative set for lung cancer primarily comprises of radiological imaging modalities such as chest radiographs and com...
Demographic inequalities in mortality due to hepatocellular cancer in male patients with alcoholic cirrhosis across the United States: A CDC WONDER database analysis.
e22558 Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and ranks as the third-leading cause of cancer-related deaths....
Clinical implication of MDM2 amplification in advanced biliary tract cancer (BTC): A propensity score-matched, retrospective cohort study of 813 patients.
4078 Background: Restoring p53 tumor suppressor activity by blocking the interaction between p53 and MDM2, its endogenous negative regulator, has emerged...
Five-year survival outcomes from CRES <sup>3</sup> T: S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
8064 Background: CRES 3 T is a multicenter, single-arm, confirmatory trial of S-1 plus cisplatin and concurrent radical-dose thora...
Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer.
5084 Background: The androgen receptor pathway inhibitor (ARPI) enzalutamide is one of the principal treatments for metastatic hormone-naïve and castratio...
Prognostic impact of DDR mutations (mt) in IDH mutant high-grade gliomas (HGG).
2066 Background: The oncometabolite 2-hydroxyglutarate (2HG) produced by IDH1/2 mt in HGG has profound effects on numerous pathway...
Impact of CAR T cell therapy product in the clinical outcome of patients with relapsed/refractory diffuse large B-cell lymphoma.
e19002 Background : The management of relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) is associated with high morbidity and mo...
A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.
TPS9596 Background: Prior studies demonstrated use of neoadjuvant plus adjuvant immune checkpoint inhibitors (ICIs) improves event-free survival (EFS) com...
FOLFOX-HAIC/TACE combined with lenvatinib plus tislelizumab as a conversion therapy in initial unresectable hepatocellular carcinoma: A retrospective real-world study.
e16201 Background: Systemic and locoregional combination therapy has demonstrated promising outcomes for unresectable hepatocellular carcinoma (uHCC). The...
Effect of BMI on CAR T-cell therapy outcomes: Real-world analysis.
e19013 Background: The escalating obesity rates in the USA are contributing to an increase in associated health complications. Limited data exists regardi...
Adherence to vaccination recommendations in the adult cancer population.
11148 Background: In 2024, the American Society of Clinical Oncology (ASCO) published a strong recommendation that clinicians should ensure that all adult...
Short-course radiotherapy followed by CAPOX combined with tislelizumab and bevacizumab or cetuximab for treatment-naive unresectable metastatic rectal cancer (UNION mRC).
e15553 Background: Doublet chemotherapy regimens based on oxaliplatin or irinotecan, combined with targeted agents such as bevacizumab or cetuximab, repre...
Patterns of feeding tube utilization in base of tongue adenoid cystic carcinoma treated with neutron radiotherapy.
e18074 Background: For locally advanced salivary cancers, primary radiotherapy is an option for unresectable disease or when resection would cause signifi...
Spillover effects of Medicaid expansion on insurance coverage, diagnosis, and survival among low-income elderly patients with cancer.
1522 Background: Medicaid expansion under the Affordable Care Act is associated with increased health insurance coverage and improved outcomes among patie...
Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.
3003 Background: TQB2102 is an antibody-drug conjugate (ADC) comprised of a recombinant, humanized anti-human epidermal gr...
Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
TPS5113 Background: Resistance to androgen receptor (AR) pathway inhibitors (ARPI; e.g., abiraterone, enzalutamide) in mCRPC may be driven by preservation...
Dual immunotherapy with nivolumab and ipilimumab for metastatic melanoma: Real-world outcomes from a single-center study.
e21541 Background: This study evaluates the efficacy and safety of dual immunotherapy with nivolumab and ipilimumab in patients with metastatic melanoma....
Cascade conversations: Empowering cancer genetic testing through Cascade chatbots.
e22621 Background: Cascade genetic testing refers to the process of offering genetic testing to blood relatives of individuals with known pathogenic mutat...
Atropisomeric pyrrolopyrimidine inhibitor as a targeted approach for RET tyrosine kinase in neuroblastoma.
3118 Background: Increased RET expression is associated with poor prognosis in children with solid tumors such as neuroblastoma (NB), prompting an interes...
A propensity-score matched analysis for time to trabectedin-failure in advanced myxoid liposarcoma patients.
11571 Background: Whether to discontinue trabectedin (T) in soft-tissue sarcoma (STS) patients (pts) with response or stable disease remains controversial...
End-of-life care for newly diagnosed diffuse large B-cell lymphoma patients with poor survival outcomes.
e24032 Background: Despite recent advances in treatment paradigms for diffuse large B-cell lymphoma (DLBCL), a subset of patients (pts) continues to face...
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
6504 Background: In pts with AML aged ≥75 years and ineligible for induction chemotherapy, the combination of the Bcl-2 in...
Clinical factors and prognostic outcomes of hyperthyroidism induced by immune checkpoint inhibitor therapy.
2620 Background: Hyperthyroidism is a recognized but less frequent immune-related adverse event (iRAE) associated with Immune Checkpoint Inhibitor (ICI) u...
Comparing anal cancer characteristics between Asian American and Pacific Islander subgroups.
e15506 Background: Analyses of anal cancer (AC) typically combine Asian Americans and Pacific Islanders (AAPI) into a single “AAPI” group. However, whethe...